Skip to main content
main-content

WCLC 2019

IASLC 2019 World Conference on Lung Cancer coverage

All the breaking news and expert interviews from the meeting in Barcelona (September 7–10).

Conference overview

The IASLC World Conference on Lung Cancer 2019 (WCLC 2019) is the largest international meeting on lung cancer and thoracic oncology. Here we provide news and expert interviews on the key data coming out of the meeting, including coverage of the LIBRETTO-001, CASPIAN and VIOLET trials.

Upcoming coverage

Conference coverage from WCLC 2019 will commence from Saturday, September 7. You can keep up to date in a number of ways:

Expert interviews

23-09-2019 | Non-small-cell lung cancer | WCLC 2019 | Article

Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’

LISTEN | Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer (3:40).

13-09-2019 | Surgery | Video | Article

Researcher comment: VIOLET results support VATS for lung cancer resection

WATCH | Eric Lim describes the findings of the VIOLET trial comparing video-assisted thoracoscopic lobectomy and open lobectomy for early-stage lung cancer (1:57).

13-09-2019 | Small-cell lung cancer | Video | Article

Expert comment: CASPIAN trial of durvalumab in SCLC

WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).

12-09-2019 | Screening | Video | Article

Researcher comment: ILST findings support novel eligibility criteria

WATCH | Stephen Lam discusses the interim findings from the International Lung Screen Trial indicating that changing eligibility criteria can improve identification of high-risk individuals (5:36).

10-09-2019 | Lung cancer | Video | Article

Researcher comment: Combining microRNAs and LDCT to assess lung cancer risk profiles

WATCH | Ugo Pastorino discusses the bioMILD study, which investigates a lung cancer screening program that supplements low-dose computed tomography with a blood microRNA assay (3:09).

10-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC

WATCH | Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).

09-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TMB not prognostic for KEYNOTE-189 participant outcomes

WATCH | Marina Garassino reports the KEYNOTE-189 tumor mutational burden analysis and what the findings mean for this biomarker (4:03).

09-09-2019 | Non-small-cell lung cancer | WCLC 2019 | Article

Researcher comment: CheckMate 817 trial of nivolumab–ipilimumab

WATCH | Is first-line nivolumab–ipilimumab a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status? Fabrice Barlesi discusses the CheckMate 817 trial (3:32).

08-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

WATCH | Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

Research news

18-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

Nivolumab confers NSCLC survival advantage over 5 years

Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.

16-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

Special NSCLC populations can benefit from nivolumab plus ipilimumab

Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.

13-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.

12-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

12-09-2019 | Screening | WCLC 2019 | News

microRNA plus LDCT guides optimal lung cancer screening intensity

Combining low-dose computed tomography with a blood microRNA test can help establish the most appropriate screening frequency among heavy smokers at risk for lung cancer, study data show.

11-09-2019 | Lung cancer | WCLC 2019 | News

VATS in-hospital outcomes may better those of open lobectomy

Video-assisted thoracic surgery lobectomy is associated with less pain, fewer in-hospital complications, and shorter hospital stays compared with open lobectomy for early-stage lung cancer, data from the VIOLET study indicate.

10-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

Durable pembrolizumab survival benefit seen in KEYNOTE-024

Three-year results from the KEYNOTE-024 trial point to the durable efficacy of pembrolizumab monotherapy when used for the first-line treatment of metastatic non-small-cell lung cancer.

09-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

TMB does not predict NSCLC pembrolizumab–chemotherapy response

Exploratory analyses from two KEYNOTE trials rule out a significant correlation between tumor mutational burden and survival of patients with non-small-cell lung cancer who are treated with pembrolizumab and chemotherapy.

09-09-2019 | Small-cell lung cancer | WCLC 2019 | News

CASPIAN: Durvalumab addition boosts SCLC survival

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

09-09-2019 | Small-cell lung cancer | WCLC 2019 | News

irAEs linked to SCLC immunotherapy clinical benefit

The development of immune-related adverse events is associated with improved clinical outcomes in response to immune checkpoint blockade in patients with small-cell lung cancer, suggests a chart review.

08-09-2019 | Non-small-cell lung cancer | WCLC 2019 | News

Treatment hope for KRAS-mutated advanced NSCLC

AMG 510, a novel KRAS inhibitor, has promising efficacy and tolerability in previously treated patients with locally advanced or metastatic non-small-cell lung cancer carrying a KRAS G12C mutation, according to phase I trial findings.

Image Credits